Absci is a biotech that uses AI to design antibody drugs and the cell lines to manufacture them, compressing discovery and production into one platform for pharma partners.
No product revenue exists; the company burns cash, with net losses of USD 0.12B in 2025 and negative gross margins, so money comes only from partnerships and equity, not operations.
Its integrated AI-driven drug creation platform is hard to replicate, but rivals like Recursion Pharmaceuticals and Schrödinger are advancing similar AI drug discovery, and Absci's lack of commercial validation weakens the barrier.
Key events, in time order
EPS miss by $0.02, revenue shortfall; ABS-201 advancing in hair loss and endometriosis
Company sets date for Q2 earnings release, a key calendar event for investors
After Truist hike, second insider buy; AMD partnership noted
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
